 | |
- close
- close
Stock Gumshoe
Feb 2
Comment
And we're back! Today, it's a biotech teaser from Brian Hicks for Steve Christ's The Wealth Advisory (we last looked at one of his a few months back, when he was predicting a big move in Geron by this Spring -- that one's still on the clock, so...
Business Wire
Jan 26
Comment
Geron Corporation (Nasdaq:GERN) today announced that it has entered into a collaboration jointly funded by Geron and a University of California Discovery Research and Training Grant to investigate the therapeutic potential of its human embryonic stem
Business Wire
Jan 15
Comment
Geron Corporation (Nasdaq:GERN) today announced that it has entered into an agreement to exchange outstanding warrants held by certain institutional investors for shares of Geron common stock. In connection with the exchange, the company sold
Business Wire
Jan 11
Comment
Geron Corporation (Nasdaq:GERN) today announced that Thomas B. Okarma, Ph.D., M.D., president and chief executive officer, will present an update of the company’s product development programs at 3:30 p.m. PST on Wednesday, January 13, 2010, at the
FierceBiotech
Jan 6
Comment
An experimental stem cell therapy in Geron's pipeline produced some promising preclinical results for glioblastoma brain cancer and prostate cancer. Researchers say that imetelstat (also called GRN163L), was able to cross the blood/brain barrier...
Business Wire
Jan 5
Comment
Geron Corporation (Nasdaq:GERN) today announced the publication of preclinical data demonstrating that its telomerase inhibitor drug, imetelstat (GRN163L), inhibited telomerase activity and reduced tumor size in xenograft models of glioblastoma, and
BusinessWeek
Jan 4
Comment
Shares of the following companies had unusual moves in U.S. trading. Stock symbols are in parentheses, and prices are as of 4 p.m. in New York.
StreetInsider.com
Jan 4
Comment
Visit StreetInsider.com at http://www.streetinsider.com/FDA/Geron+%28GERN%29+Higher+Following+Positive+Trial+Results/5215835.html for the full story.
Suggest other news sources for this topic
Thank you for your suggestion
more ▼WIKI ANALYSIS
WIKI ANALYSIS
 |
The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article. |
References
| ||||||
